{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:54:55Z","timestamp":1770486895876,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.neuropharm.2016.07.013","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T18:35:25Z","timestamp":1469644525000},"page":"268-276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"PA","title":["Wake-promoting effects of ONO-4127Na, a prostaglandin DP1 receptor antagonist, in hypocretin\/orexin deficient narcoleptic mice"],"prefix":"10.1016","volume":"110","author":[{"given":"Yohei","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Chikahisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-0244","authenticated-orcid":false,"given":"Junki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2016.07.013_bib2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","article-title":"Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation","volume":"98","author":"Chemelli","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2016.07.013_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.expneurol.2009.01.015","article-title":"Specificity of direct transition from wake to REM sleep in orexin\/ataxin-3 transgenic narcoleptic mice","volume":"217","author":"Fujiki","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2016.07.013_bib4","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/sleep\/26.8.953","article-title":"Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog","volume":"26","author":"Fujiki","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2016.07.013_bib5","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/sleep\/32.11.1425","article-title":"The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents","volume":"32","author":"Gruner","year":"2009","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2016.07.013_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.coph.2006.09.004","article-title":"Prostaglandins and adenosine in the regulation of sleep and wakefulness","volume":"7","author":"Huang","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.07.013_bib7","series-title":"International Classification of Sleep Disorders","author":"ICSD-3","year":"2014"},{"key":"10.1016\/j.neuropharm.2016.07.013_bib8","first-page":"1372","article-title":"Narcolepsy increased L-PGDS (beta-trace) levels correlate with excessive daytime sleepiness but not with cataplexy","volume":"252","author":"Jordan","year":"2005","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.neuropharm.2016.07.013_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0013-4694(85)91073-9","article-title":"Electroencephalographic correlates of cataplectic attacks in narcoleptic canines","volume":"61","author":"Kushida","year":"1985","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2016.07.013_bib10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","article-title":"The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene","volume":"98","author":"Lin","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2016.07.013_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0165-0270(94)00107-R","article-title":"A\u00a0novel apparatus that permits multiple routes for infusions and body-fluid collections in a freely-moving animal","volume":"57","author":"Matsumura","year":"1995","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2016.07.013_bib12","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","article-title":"The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias","volume":"59","author":"Mignot","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2016.07.013_bib13","doi-asserted-by":"crossref","first-page":"11674","DOI":"10.1073\/pnas.201398898","article-title":"Dominant localization of prostaglandin D receptors on arachnoid trabecular cells in mouse basal forebrain and their involvement in the regulation of non-rapid eye movement sleep","volume":"98","author":"Mizoguchi","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.07.013_bib14","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1021\/acs.jmedchem.5b00988","article-title":"Design and synthesis of non-peptide, selective orexin receptor 2 agonists","volume":"58","author":"Nagahara","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2016.07.013_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0301-0082(96)00070-6","article-title":"Pharmacological aspects of human and canine narcolepsy","volume":"52","author":"Nishino","year":"1997","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2016.07.013_bib16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/smrv.1999.0069","article-title":"Narcolepsy: genetic predisposition and neuropharmacological mechanisms","volume":"4","author":"Nishino","year":"2000","journal-title":"Sleep. Med. Rev."},{"key":"10.1016\/j.neuropharm.2016.07.013_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1748-1716.2009.02012.x","article-title":"Hypocretin\/orexin and narcolepsy: new basic and clinical insights","volume":"198","author":"Nishino","year":"2010","journal-title":"Acta Physiol. (Oxf)"},{"key":"10.1016\/j.neuropharm.2016.07.013_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","article-title":"Hypocretin (orexin) deficiency in human narcolepsy","volume":"355","author":"Nishino","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2016.07.013_bib19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ana.1130","article-title":"Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy","volume":"50","author":"Nishino","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2016.07.013_bib20","series-title":"Principles and Practice of Sleep Medicine","article-title":"CNS stimulants in sleep medicine: basic mechanisms and pharmacology","author":"Nishino","year":"2005"},{"key":"10.1016\/j.neuropharm.2016.07.013_bib21","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/sleep\/33.7.930","article-title":"Effects of paraxanthine and caffeine on sleep, locomotor activity, and body temperature in orexin\/ataxin-3 transgenic narcoleptic mice","volume":"33","author":"Okuro","year":"2010","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2016.07.013_bib22","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0035-9203(90)90085-S","article-title":"The somnogenic T lymphocyte suppressor prostaglandin D2 is selectively elevated in cerebrospinal fluid of advanced sleeping sickness patients","volume":"84","author":"Pentreath","year":"1990","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.neuropharm.2016.07.013_bib23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/79690","article-title":"A\u00a0mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains","volume":"6","author":"Peyron","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2016.07.013_bib24","doi-asserted-by":"crossref","first-page":"17949","DOI":"10.1073\/pnas.0608581103","article-title":"Lipocalin-type prostaglandin D synthase produces prostaglandin D2 involved in regulation of physiological sleep","volume":"103","author":"Qu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.07.013_bib25","series-title":"A\u00a0Manual of Standardized Terminology, Techniques, and Scoring System for Sleep Stages of Human Subjects","year":"1968"},{"key":"10.1016\/j.neuropharm.2016.07.013_bib26","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1056\/NEJM198012113032405","article-title":"Increased production of prostaglandin D2 in patients with systemic mastocytosis","volume":"303","author":"Roberts","year":"1980","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2016.07.013_bib27","doi-asserted-by":"crossref","first-page":"7754","DOI":"10.1073\/pnas.95.13.7754","article-title":"Activation of ventrolateral preoptic neurons by the somnogen prostaglandin D2","volume":"95","author":"Scammell","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.07.013_bib28","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1001\/jama.2009.351","article-title":"Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications","volume":"301","author":"Volkow","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2016.07.013_bib29","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1046\/j.0953-816x.2001.01725.x","article-title":"Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities","volume":"14","author":"Yoshida","year":"2001","journal-title":"Eur. J. Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816302994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816302994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T12:17:46Z","timestamp":1572610666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390816302994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":28,"alternative-id":["S0028390816302994"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.07.013","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Wake-promoting effects of ONO-4127Na, a prostaglandin DP1 receptor antagonist, in hypocretin\/orexin deficient narcoleptic mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}